Bolt Biotherapeutics Announces Reverse Stock Split Approval

Bolt Biotherapeutics ( (BOLT) ) has shared an update.

On May 27, 2025, Bolt Biotherapeutics‘ Board of Directors approved a one-for-twenty reverse stock split, effective June 6, 2025. This move, intended to consolidate shares and adjust the exercise price of stock options, will see the company’s stock begin trading on a split-adjusted basis on June 9, 2025, under the ticker ‘BOLT’.

The most recent analyst rating on (BOLT) stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on Bolt Biotherapeutics stock, see the BOLT Stock Forecast page.

Spark’s Take on BOLT Stock

According to Spark, TipRanks’ AI Analyst, BOLT is a Neutral.

Bolt Biotherapeutics faces significant challenges in financial performance and valuation, with ongoing losses impacting its attractiveness to investors. The technical analysis shows bearish signals, suggesting weak market sentiment. Structural improvements are necessary for enhancing financial health and stock performance.

To see Spark’s full report on BOLT stock, click here.

More about Bolt Biotherapeutics

Bolt Biotherapeutics operates in the biotechnology industry, focusing on the development of immuno-oncology therapeutics. The company is dedicated to creating innovative treatments that harness the power of the immune system to combat cancer.

Average Trading Volume: 323,322

Technical Sentiment Signal: Sell

Current Market Cap: $11.71M

See more data about BOLT stock on TipRanks’ Stock Analysis page.